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ABSTRACT
Objectives To update a 2005 Cochrane review that
assessed the effects of neuraminidase inhibitors in
preventing or ameliorating the symptomsof influenza, the
transmission of influenza, and complications from
influenza in healthy adults, and to estimate the frequency
of adverse effects.
Search strategy An updated search of the Cochrane
central register of controlled trials (Cochrane Library
2009, issue 2), which contains the Acute Respiratory
Infections Group’s specialised register, Medline (1950-
Aug 2009), Embase (1980-Aug 2009), and post-
marketing pharmacovigilance data and comparative
safety cohorts.
Selection criteriaRandomised placebo controlled studies
of neuraminidase inhibitors in otherwise healthy adults
exposed to naturally occurring influenza.
Main outcome measures Duration and incidence of
symptoms; incidence of lower respiratory tract infections,
or their proxies; and adverse events.
Data extraction Two reviewers applied inclusion criteria,
assessed trial quality, and extracted data.
Data analysis Comparisons were structured into
prophylaxis, treatment, and adverse events, with further
subdivision by outcome and dose.
Results 20 trials were included: four on prophylaxis, 12
on treatment, and four on postexposure prophylaxis. For
prophylaxis, neuraminidase inhibitors had no effect
against influenza-like illness or asymptomatic influenza.
The efficacy of oral oseltamivir against symptomatic
laboratory confirmed influenza was 61% (risk ratio 0.39,
95% confidence interval 0.18 to 0.85) at 75 mg daily and
73% (0.27, 0.11 to 0.67) at 150 mg daily. Inhaled
zanamivir 10 mg daily was 62% efficacious (0.38, 0.17 to
0.85). Oseltamivir for postexposure prophylaxis had an
efficacy of 58% (95% confidence interval 15% to 79%)
and 84% (49% to 95%) in two trials of households.
Zanamivir performed similarly. The hazard ratios for time
to alleviation of influenza-like illness symptoms were in
favour of treatment: 1.20 (95% confidence interval 1.06
to 1.35) for oseltamivir and 1.24 (1.13 to 1.36) for
zanamivir. Eight unpublished studies on complications
were ineligible and therefore excluded. The remaining
evidence suggests oseltamivir did not reduce influenza
related lower respiratory tract complications (risk ratio
0.55, 95% confidence interval 0.22 to 1.35). From trial
evidence, oseltamivir induced nausea (odds ratio 1.79,
95% confidence interval 1.10 to 2.93). Evidence of rarer
adverse events from pharmacovigilance was of poor
quality or possibly under-reported.
Conclusion Neuraminidase inhibitors have modest
effectiveness against the symptoms of influenza in
otherwise healthy adults. The drugs are effective
postexposure against laboratory confirmed influenza, but
this is a small component of influenza-like illness, so for
this outcome neuraminidase inhibitors are not effective.
Neuraminidase inhibitors might be regarded as optional
for reducing the symptoms of seasonal influenza. Paucity
of good data has undermined previous findings for
oseltamivir’s prevention of complications from influenza.
Independent randomised trials to resolve these
uncertainties are needed.
INTRODUCTION
Neuraminidase inhibitors comprise nebulised zanami-
vir (Relenza; Glaxo Wellcome) and oral oseltamivir
(Tamiflu; Gilead Sciences and F Hoffmann-La
Roche), and others still under development for parent-
eral or long acting use.1 Inhibiting neuraminidase—
which, as with haemagglutin, is specific to influenza—
blocks the exit of the influenza virus from the host cell,
thereby preventing replication in other than a few host
cells.2
The use of neuraminidase inhibitors has increased
dramatically with the spread of the influenza
A/H1N1 pandemic that began in April 2009, a novel
and potentially serious infection. Partly because of the
rise in resistance to amantadine and rimantadine and
the lack of an effective vaccine, neuraminidase inhibi-
tors became a widespread public health intervention.
Their use for early containment and interruption was
also recommended in many pandemic plans, and the
World Health Organization had previously encour-
aged member countries to gain experience with
them.3
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Although several systematic reviews of the effects of
neuraminidase inhibitors are published, none system-
atically investigated the potential harms of the drugs.4-9
In addition, our previous Cochrane review6 summary
of the evidence on the effects of oseltamivir on lower
respiratory tract complications was criticised byHaya-
shi through the public Cochrane reviews feedback
mechanism (see web extra on bmj.com). This criticism
centred on one paper in particular, a meta-analysis of
the effects of oseltamivir on complications of
influenza.10 Only two of 10 randomised sets of data
had been published, and Hayashi was concerned that
informationwas insufficient to assessmethods, reliabil-
ity, and applicability of the eight remaining datasets.
In updating our review we addressed these addi-
tional concernswhile answering the original questions:
what is the evidence on the effects of neuraminidase
inhibitors in preventing or ameliorating influenza,
transmission of the virus, and influenza related compli-
cations in otherwise healthy adults, and what is the fre-
quency of adverse effects? Our original review had
found positive evidence on all of these effects, and
gastrointestinal harms.
METHODS
Weupdated a searchpreviously undertaken in any lan-
guage for randomised or quasirandomised studies that
compared oseltamivir or zanamivir in otherwise
healthy people exposed to naturally occurring influ-
enza, against placebo, control antivirals, or no inter-
vention (or compared doses or schedules of the
neuraminidase inhibitors) with the outcomes of influ-
enza (efficacy) or influenza-like illness (effectiveness).6
We excluded experimental influenza challenge studies
as their generalisability and comparability with field
studies is uncertain. Studies had to include 75% or
more of patients aged 14-60 (excluding older people
at higher risk of complications). The updated search
is summarised in the web extra. It included checking
the references of other systematic reviews.4 5 7-9
Two of us separately read all titles and studies
retrieved in the search and applied inclusion criteria.
Disagreements were resolved by discussion with a
third reviewer. Data were extracted on to standard
forms, checked, and recorded. Assessing for risk of
bias (using established criteria)11 became a major
focus of this review.
Among complications we included a combined out-
come of pneumonia, bronchitis, sinusitis, and otitis
media requiring antibiotics in people with laboratory
confirmed influenza. We were unable to meta-analyse
the same outcomes reported by Kaiser et al10 because
the data for those outcomes were not available to us for
individual trials.We carried out a sensitivity analysis of
complications by excluding the unpublished trials
included in the Kaiser review criticised by Hayashi.
Weused randomeffectsmethods to comparedichot-
omous outcomes (risk ratio for efficacy and odds ratio
for safety); therefore estimates meta-analysed over
multiple trials are average treatment effects. Where
hazard ratios were not provided we converted the
ratio of medians of treatment groups into (log) hazard
ratios (estimating the variance of these)12 to enable
meta-analysis of time to event outcomes.
We carried out an additional search for evidence of
harms, including submitting a Freedomof Information
Act request to the US Food and Drug Administration
for all data on the harms of oseltamivir and
zanamivir.13 We also pursued authors of some papers
and manufacturers in attempts to disentangle sum-
marised or conflated data.
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 search of database (n=399)
New studies included in quantitative
synthesis (meta-analysis) (n=0)
Records excluded (n=389)
Studies included in qualitative synthesis (n=0)
Full text articles excluded, with reasons (n=10);
data from one meta-analysis10 included in previous
versions of Cochrane review were excluded
Fig 1 | Flow of studies identified from 2009 update of
randomised controlled trials
Records after duplicates removed (n=1416)
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Studies included in quantitative synthesis
(meta-analysis) (n=0); in addition, data from
US and Japanese regulatory websites were evaluated39-41
Records excluded (n=1396)
Studies included in qualitative synthesis (n=2);
excluded from effectiveness part of review
but provided data on adverse events14 15
Full text articles excluded, with reasons (n=18)
Fig 2 | Flow of studies identified from search for evidence from
post-marketing studies (excluding adverse event reporting
system)
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RESULTS
Overall, 29 studies made up of 10 effectiveness and 10
safety studies (six were identified by both searches)
were excluded, together with a further three effective-
ness studies, excluded after more deliberation (figs 1
and 2). 10 14 15 This left 20 included trials in 19
publications. 16-34 Two studies that were excluded
from the effectiveness outcomequestionwere included
in the safety data sources. 14 15 (See web extra for details
of the included and excluded studies.)
Quality of evidence
On the basis of the published text only five trials were
judged adequate by usual Cochrane Collaboration
methods35: one trial on prophylaxis30 and four on
treatment.25 27 31 33 Most of the trials were at risk of
bias, arising from poor descriptions of the
methods,10 16 17 21-23 36 such as no description of losses
to follow-up and blinding.21 Attempts to deal with
these shortcomings were unsuccessful: although three
of five first authors of studies on oseltamivir treatment
responded to our contact, none had original data and
referred us to themanufacturer (Roche), whichwas not
able to unconditionally provide the information as
quickly as we needed it to update this review.37 One
meta-analysis10 was made up of data from 10 studies.
Wewere obliged to exclude thismeta-analysis because
we were unable to determine the number of healthy
adults experiencing complications in each study
(some studies contained mixed populations of healthy
and comorbid participants), nor the number of patients
experiencing one or more of “bronchitis, lower
respiratory tract infection, or pneumonia” presenting
to each study.
Evidence of benefits
Prophylaxis against influenza
We found no new studies of benefit fulfilling our cri-
teria. Two trials compared a total of 697 adults treated
with inhaled zanamivir 10 mg daily and 602 with pla-
cebo (followed for 22 days),21 30 and two trials com-
pared 675 adults treated with oral oseltamivir 75 mg
daily and 413 with placebo (followed for 49 days).22 36
Evidencewas insufficient to support or refute the effect
of neuraminidase inhibitors on prophylaxis of influ-
enza-like illness: risk ratio 1.28 (95% confidence inter-
val 0.45 to 3.66) for oseltamivir and 1.51 (0.77 to 2.95)
for zanamivir.19 21 36 Higher dosages made no differ-
ence, although this conclusion is based on a single
study with only nine events (fig 3). 36
Zanamivir reduced the chance of symptomatic
laboratory confirmed influenza (0.38, 0.17 to 0.85 for
10 mg daily). Oseltamivir was similarly efficacious
(0.39, 0.18 to 0.85 for 75 mg daily; fig 4). Neither pro-
tected against asymptomatic influenza.22 30 36
Postexposure prophylaxis against influenza
Postexposure prophylaxis against influenza entails giv-
ing exposed people neuraminidase inhibitors before
symptoms develop. Two zanamivir trials reported sig-
nificant protection for households (risk ratios 0.1930
and 0.219) and two oseltamivir trials reported similar
results (0.1634 and 0.4218).
Treatment
Eight trials of zanamivir treatmentwere included in the
current review,16 17 20 25-28 32 of which two1617 were
linked to others27 28 (a total of 1878 participants in the
treatment armand1310 controls,with amean lengthof
follow-up of 26 days). Five trials of oseltamivir were
also included,10 24 31 33 38 one10 with supplementary out-
come data from previous trials and another 24 linked to
a redundant publication38 (totalling 1118 participants
in the treatment arm and 679 controls, with a mean
length of follow-up of 21 days).
There was evidence of benefit in shortening the
duration of influenza-like illness for zanamivir (hazard
Oral oseltamivir 75 mg daily
  Hayden 199936
  Kashiwagi 200022
Subtotal (95% CI)
Heterogeneity: τ2=0.36, χ2=2.34, df=1, P=0.13, I2=57%
Test for overall effect: z=0.46, P=0.64
Oral oseltamivir 150 mg daily
  Hayden 199936
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: z=0.01, P=1.00
Inhaled zanamivir 10 mg daily
  Kaiser 200021
  Monto 199930
Subtotal (95% CI)
Heterogeneity: τ2=0.06, χ2=1.15, df=1, P=0.28, I2=13%
Test for overall effect: z=1.19, P=0.23
Intranasal zanamivir 6.4 mg daily
  Kaiser 200021
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: z=0.34, P=0.73
Inhaled and intranasal zanamivir 10 mg and 6.4 mg daily
 Kaiser 200021
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: z=1.39, P=0.16
Total (95% CI)
Total events
Heterogeneity: τ2=0.09, χ2=8.13, df=6, P=0.23, I2=26%
Test for overall effect: z=0.82, P=0.41
0.63 (0.17 to 2.31)
1.91 (1.07 to 3.42)
1.28 (0.45 to 3.66)
1.00 (0.25 to 3.95)
1.00 (0.25 to 3.95)
0.67 (0.13 to 3.53)
1.74 (1.00 to 3.02)
1.51 (0.77 to 2.95)
0.79 (0.21 to 2.95)
0.79 (0.21 to 2.95)
0.33 (0.07 to 1.58)
0.33 (0.07 to 1.58)
1.20 (0.77 to 1.87)
5/520
29/155
675
6/520
520
4/144
33/553
697
7/141
141
3/146
146
2179
87
0.005 0.1 1 10 200
Favours
neuraminidase
inhibitors
Favours
placebo
Risk ratio (random
effects) (95% CI)
Risk ratio (random 
effects) (95% CI)
9.5
28.8
38.3
8.7
8.7
6.3
30.3
36.6
9.5
9.5
7.0
7.0
100.0
Weight
(%)
Neuraminidase
inhibitors
No of events/Total
No of participants
4/260
15/153
413
3/259
259
2/48
19/554
602
3/48
48
3/48
48
1370
49
Placebo
Fig 3 | Effect of neuraminidase inhibitors compared with placebo on prophylaxis against
influenza-like illness
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ratio 1.24, 95% confidence interval 1.13 to 1.36) and
for oseltamivir (1.20, 1.06 to 1.35; fig 5) if taken within
48 hours of the onset of symptoms.
Data on the effectiveness of oseltamivir against com-
plications of influenza principally came from one
study,10 as pointed out by Hayashi (see web extra).
This was a meta-analysis of 10 trials containing a mix-
ture of published and unpublished data, two of which
are reported in this update and the remainder inacces-
sible to proper scrutiny, so that we are now obliged to
disregard them. The remaining data showed no benefit
for oseltamivir against complications (fig 6).
Evidence on harms of neuraminidase inhibitors
Two of the studies excluded for addressing the benefits
of neuraminidase inhibitors question nevertheless
provided information on the harms of oseltamivir.14 15
Eighteen safety studies were included. This left 20
included trials in 19 publications.16-34 We also exam-
ined two sources of pharmacovigilance data describing
reported adverse events from the FDA adverse event
reporting system (AERS), one obtained by request
using the Freedom of Information Act, “AERS-1”,
and another accessed directly from two FDAwebsites,
“AERS-2.”39 40 Another dataset containing reports of
adverse events was located on a website by the Japa-
nese Pharmaceuticals and Medical Devices Agency.41
We were unable to gain the same access to data from
the European Medicines Agency.42 The table sum-
marises the characteristics of the data sources.
Quality of evidence
In total, 1416 titles were found, most for oseltamivir,
and we discarded all except for 20 studies of different
design, the two sources of pharmacovigilance data
from the AERS, and the Japanese data.13 39-41 The Japa-
nese data contained tables of adverse events occurring
in manufacturer funded clinical trials, and included
individual patient level data.
Both FDA datasets include post-licensure adverse
event reports (voluntary and mandatory) from a vari-
ety of sources, including consumers, healthcare provi-
ders, and manufacturer. Reports in the FDA AERS
database are of three types: “expedited (15-day)” and
“periodic,” which are mandatory reports from manu-
facturers, and “direct,” which are reports voluntarily
submitted by non-manufacturers. The two manufac-
turer channels comprised 2062/2275 (90.6%) of all
reports on oseltamivir from the AERS. All adverse
events that are “both serious and unexpected” must,
according to FDA rules, be reported bymanufacturers
within 15 days of initial receipt of information about
the event. “Serious,” by the FDA’s definition, are
those events that result in “Death, a life-threatening
adverse drug experience, inpatient hospitalization or
prolongation of existing hospitalization, a persistent
or significant disability/incapacity, or a congenital
anomaly/birth defect.”43 For all other adverse events,
reporting requirements differ on the basis of the origin
of the information. Not all notices of adverse events
received by the FDA are necessarily entered into the
AERS.
The Japanese data contained tables of adverse
events, including individual patient level data for ser-
ious adverse events.41 However, these were discarded
because of irreconcilable differences in serious adverse
events reported here but apparently not reported in
two published trials.31 33
Evidence of harms
The trials identified only one serious adverse event31
(so labelled in the Japanese data, a patient with neutro-
penia), and, in particular, no neuropsychiatric events.
Oseltamivir induced nausea (odds ratio 1.79, 95% con-
fidence interval 1.10 to 2.93), especially at the higher
dose of 150 mg daily (2.29, 1.34 to 3.92; fig 7). No
Oral oseltamivir 75 mg daily
  Hayden 199936
  Kashiwagi 200022
Subtotal (95% CI)
Heterogeneity: τ2=0.12, χ2=1.59, df=1, P=0.21, I2=37%
Test for overall effect: z=2.36, P=0.02
Oral oseltamivir 150 mg daily
  Hayden 199936
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: z=2.84, P=0.005
Inhaled zanamivir 10 mg daily
  Kaiser 200021
  Monto 199930
Subtotal (95% CI)
Heterogeneity: τ2=0.22, χ2=2.90, df=1, P=0.09, I2=66%
Test for overall effect: z=2.35, P=0.02
Intranasal zanamivir 6.4 mg daily
  Kaiser 200021
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: z=0.17, P=0.87
Inhaled and intranasal zanamivir 10 mg and 6.4 mg daily
 Kaiser 200021
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: z=3.04, P=0.002
Total (95% CI)
Total events
Heterogeneity: τ2=0.23, χ2=14.80, df=6, P=0.02, I2=59%
Test for overall effect: z=3.80, P<0.001
0.25 (0.09 to 0.66)
0.56 (0.25 to 1.22)
0.39 (0.18 to 0.85)
0.27 (0.11 to 0.67)
0.27 (0.11 to 0.67)
0.59 (0.28 to 1.25)
0.26 (0.15 to 0.47)
0.38 (0.17 to 0.85)
1.06 (0.54 to 2.08)
1.06 (0.54 to 2.08)
0.22 (0.08 to 0.58)
0.22 (0.08 to 0.58)
0.41 (0.25 to 0.65)
6/520
9/155
675
7/520
520
16/144
14/553
697
26/141
141
6/146
146
2179
86
0.005 0.1 1 10 200
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Risk ratio (random 
effects) (95% CI)
Risk ratio (random 
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26.4
12.7
12.7
15.0
17.9
32.9
16.2
16.2
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11.8
100.0
Weight
(%)
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12/259
16/153
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9/48
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Fig 4 | Effect of neuraminidase inhibitors compared with placebo on prophylaxis against
laboratory confirmed influenza
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statistically significant adverse event was found for
zanamivir from trials. 26-28 32
Two published studies reported additional retro-
spective comparative safety data on oseltamivir.14 15
Their data suggest an incidence of neuropsychiatric
adverse events per 1000 adults aged 18-49 of 20-27 at
14 days and 30-40 at 30 days,14 and for neuropsychia-
tric adverse events in prospective clinical trials, an inci-
dence of 0.5%.15
AERS-1includes 2275 adverse event reports for
oseltamivir and 453 for zanamivir (excluding follow-
up reports on the same individual event) generated
worldwide between December 1999 and July 2009
(the month our request was answered). Unfortunately
it indicates neither reporting country nor how long the
event occurredbefore receipt of the report by the FDA.
The period from2004 onwards overlapswithAERS-2,
which has reports from January 2004 to March 2009,
indicating both initial and follow-up reports, and
reporting the date of the adverse event.39 40 From July
2005 it indicates the reporting country. From July 2005
to March 2009, 1205 initial adverse events occurred.
Most (681, 56.5%) were reported from Japan, followed
by the United States (390, 32.4%). Most (1109, 92.0%)
were for oseltamivir (perhaps reflecting its higher use).
A disproportionate amount of reports are for people
aged less than 20 (with data on age missing for many).
DISCUSSION
The data suggest that neuraminidase inhibitors are
effective at reducing the symptoms of influenza. The
evidence is of modest benefit—reduction of illness by
about one day. This benefit has been generalised to
assume benefits for very ill people in hospital. This
seems reasonable, although it is worth remembering
that we have no data to support this, and it is unlikely
that ethics committees would allow a trial of no treat-
ment for people with influenza who have life threaten-
ing disease.
Zanamivir
  Hayden 199720
  Makela 200025
  Matsumoto 199926
  MIST 199827
  Monto 199928
  Puhakka 200332
Subtotal (95% CI)
Heterogeneity: τ2=0.00, χ2=4.41, df=5, P=0.49, I2=0%
Test for overall effect: z=4.48, P<0.001
Oseltamivir
  Li 200324
  Nicholson 200031
  Treanor 200033
Subtotal (95% CI)
Heterogeneity: τ2=0.00, χ2=2.67, df=2, P=0.26, I2=25%
Test for overall effect: z=2.96, P=0.003
Total (95% CI)
Heterogeneity: τ2=0.00, χ2=7.32, df=8, P=0.50, I2=0%
Test for overall effect: z=5.64, P<0.001
1.11 (0.88 to 1.40)
1.50 (1.19 to 1.89)
1.33 (0.83 to 2.16)
1.30 (1.06 to 1.60)
1.17 (1.01 to 1.35)
1.23 (0.24 to 6.34)
1.24 (1.13 to 1.36)
1.05 (0.87 to 1.27)
1.24 (1.05 to 1.47)
1.29 (1.08 to 1.53)
1.20 (1.06 to 1.35)
1.22 (1.14 to 1.31)
273
174
77
227
834
293
1878
216
484
418
1118
2996
0.10.215 0.5210
Favours
neuraminidase
inhibitors
Favours
placebo
Hazard ratio
(random effects)
(95% CI)
Hazard ratio
(random effects)
(95% CI)
8.9
8.9
2.1
11.4
22.5
0.2
54.0
13.3
17.1
15.6
46.0
100.0
Weight
(%)
Neuraminidase
inhibitors
Total
144
182
39
228
422
295
1310
235
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209
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1989
Placebo
0.105
0.405
0.288
0.262
0.154
0.207
0.049
0.216
0.253
log (hazard
ratio)
0.1183
0.1183
0.2449
0.1048
0.0744
0.8366
0.0969
0.0854
0.0894
SE
Fig 5 | Effect of neuraminidase inhibitors compared with placebo on alleviation of influenza
symptoms (intention to treat analysis)
Summary of databases on adverse effects of neuraminidase inhibitors
Data source Who reports What is reported Date range of contents Comments
US FDA AERS-1 (obtained
through Freedom of
Information Act request)
Manufacturers under mandatory
reporting requirements in accordance
with FDA Code of Federal Regulations
title 21 section 314.80; health
professionals and consumers report
voluntarily
Post-marketing surveillance adverse event reports occurring
in US and abroad. For adverse events occurring in US,
manufacturers must report to FDA all adverse events except
for labelled non-serious events (assuming companies have
been granted such a waiver). For non-US events,
manufacturers are only required to report adverse events
that are “both serious and unexpected.” For first three years
after approval, FDA enters all adverse events into AERS
database. After three years, all electronically submitted and
all “serious” adverse events are entered into AERS
Aug 1999 (zanamivir) and
Dec 1999 (oseltamivir) to
Jul 2009
Date of event, timing in
relation to drug, country of
report unclear
US FDA AERS-239 40 Manufacturers under mandatory
reporting requirements in accordance
with FDA Code of Federal Regulations
title 21 section 314.80; health
professionals and consumers report
voluntarily
Post-marketing surveillance adverse event reports occurring
in US and abroad. For adverse events occurring in US,
manufacturers must report to FDA all adverse events except
for labelled non-serious events (assuming companies have
been granted such a waiver). For non-US events,
manufacturers are only required to report adverse events
that are “both serious and unexpected.” For first three years
after approval, FDA enters all adverse events into AERS
database. After three years, all electronically submitted and
all “serious” adverse events are entered into AERS
Jan 2004 to Mar 2009 More detailed reports
indicatingreportingcountry
consistently from Jul 2005.
Reporting of
neuropsychiatric adverse
events more common
among children and
adolescents taking
oseltamivir, but relation to
drug is unclear48
Japanese Pharmaceuticals
and Medical Devices
Agency41
Documents reviewedweresubmittedby
Chugai Pharmaceutical to Japanese
regulators in conjunction with new drug
application for prophylactic use of
Tamiflu 75mg capsules
Summary adverse events occurring in treatment trial protocol
numbers WV15670, WV15671, and WV15730. Individual
patient level description of serious adverse events occurring
during these three trial protocols while receiving treatment
(six participants), not receiving treatment (two participants),
and resulting in early withdrawal (12 participants)
Event dates not given;
using trial date rates,
events occurred between
Dec 1997 and Sep 1998
No cases of
neuropsychiatric adverse
events were reported in
trials of otherwise healthy
adults
FDA=Food and Drug Administration; AERS=adverse events reporting system.
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One important caveat to these results arises from
concerns about the difference between efficacy (treat-
ment response to pure influenza virus infection) and
effectiveness (the real life response to influenza-like ill-
ness, when real cases of influenza are indistinguishable
fromother causative agents not responsive to neurami-
nidase inhibitors44). Understanding the proportion of
influenza-like illness caused by both seasonal and epi-
demic influenza is critical to generalising the results of
this review to clinical practice. The findingof treatment
effectiveness for the neuraminidase inhibitors may
have been enhanced by the high percentage of influ-
enza-like illness caused by influenza in most of the
included trials—for example, up to 80%.23
Data on the effectiveness of oseltamivir against the
complications of influenza are confusing. Hayashi
pointed out that the original data, which led to the
2005 version of this original Cochrane review report-
ing benefits for oseltamivir on reduction of complica-
tions from lower respiratory tract infection, principally
came fromonemeta-analysis that summarised 10 trials
containing a mixture of published and unpublished
data.10 Only two of the trials it contains are published
(and are reported in this Cochrane review update), the
remainder were offered to us under conditions we
thought unacceptable, and what was offered to us was
insufficient to analyse properly. (Comments on the
Kaiser et al paper are in the web extra). This means
we are now obliged to exclude the meta-analysis.10
The remaining published evidence is insufficient to
answer the question about the effectiveness of either
neuraminidase inhibitor on reducing the complica-
tions of lower respiratory tract infection, antibiotic
use, or admissions to hospital. It is possible that there
is a publication bias, especially as we know of eight
trials that are unpublished and inaccessible. We have
not undertaken a funnel plot because there are only
three trials (fig 6), and so the issue of publication bias
remains unresolved. Its directionmight be in favour of
exaggerating the treatment effect. Hayashi’s com-
ments point out a serious problem with our original
review, which we now address.
The results from themeta-analyses involving hazard
ratios should be viewed with caution because of the
approximate methods used to extract estimates for
each study. Hazard ratios were rarely reported
directly, sowehad to use the ratio of the observedmed-
ian duration of symptoms in each group as an approx-
imation to the hazard ratio. This approach may be
overly simplistic, as it makes a comparison at only
one time point and assumes a constant survival differ-
ence over time, and thus may produce different meta-
analysis results than if the actual hazard ratio estimates
were available.45
Role of neuraminidase inhibitors in seasonal influenza
Neuraminidase inhibitors had low effectiveness and
high efficacy against symptoms (shortening the illness
by half to one day, a crude estimatemade by applying a
hazard ratio of 1.2 on the control length of illness of
four days to about 3.3 days, a reduction of less than
one day, and preventing symptoms from appearing),
and initially seemed to be well tolerated (with the pos-
sible exception of oseltamivir induced nausea and
vomiting).
A surprising finding was the high percentage (57-
80%)23 of influenza in the trial populations receiving
neuraminidase inhibitors. We remain at a loss to
explain this because most other data suggest much
lower rates.46
Role of neuraminidase inhibitors in pandemic influenza
We identified no direct comparative evidence of the
role of neuraminidase inhibitors in avian influenza
A/H5N1 or in the current novel influenza A/H1N1
pandemic. This means that we have to generalise
from the trials, and this seems reasonable given that
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the pandemic influenza A/H1N1 virus will likely be
acted on in the same biological manner as previously
circulating influenza viruses, such as seasonal
A/H1N1.
Neuraminidase inhibitors do not, however, prevent
infection or stop nasal viral excretion, so theymay be a
suboptimalmeans of interrupting viral spread in a pan-
demic. If used to contain a severe pandemic outbreak,
neuraminidase inhibitors should be considered only
part of a package of measures to interrupt spread,
including physical measures.47
Possible harms of neuraminidase inhibitors
We focused on oseltamivir because of the considerably
greater global experience with this drug. Post-market-
ing pharmacovigilance data about oseltamivir
obtained from the FDA are of limited use because of
likely under-representation of reports generated from
outside the United States. The entire AERS database
(containing adverse event reports of all types) between
1999 and 15 September 2007 contains only 1805
reports. However, the Roche global safety database
contains reports of 2466 neuropsychiatric adverse
events during this time, ofwhich 562 (22.8%)were clas-
sified as “serious.”15
Another important limitation of the AERS database
is the practice by the FDA of not registering non-elec-
tronically submitted reports of non-serious adverse
events three years after a drug’s initial approval (per-
sonal correspondence with FDA, 14 October 2009).
Our findings of a possible association with neurami-
nidase inhibitors and the onset of rare harms coming
from theUSAERSdata48 accordwith a reviewof phase
IV evidence from eight cases (adolescents and
adults),49 suggesting oseltamivir may induce sudden
behavioural changes in recipients, including hallucina-
tion, suicidal tendencies, and sudden death while
asleep. This evidence came soon after a reviewordered
by the Japanese government, in part triggered by the
567 serious neuropsychiatric cases received since the
2001 launchof thedrug andMay2007.49 It is, however,
estimated that more than 36 million doses have been
prescribed since 2001,15 making such harms (even if
confirmed) rare.
We therefore found under-reported evidence of var-
ied quality, which could not answer concerns about the
toxicity of neuraminidase inhibitors, especially oselta-
mivir. Governments should set up studies to monitor
the safety of neuraminidase inhibitors.48
Conclusion
Because of the moderate effectiveness of neuramini-
dase inhibitors, we believe they should not be used in
routine control of seasonal influenza.We are unsure of
the generalisability of our conclusions from seasonal to
pandemic influenza. Evidence on the effects of oselta-
mivir in complications from lower respiratory tract
infections, reported in our 2006 Cochrane review,
may be unreliable. Evidence on serious harms of neur-
aminidase inhibitors is limited. Independent rando-
mised trials to resolve the uncertainties surrounding
effectiveness are needed.
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